SEC Form 4 · accession 0001739090-26-000010
Scribe Therapeutics, Inc. · SCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer A Doudna
10% Owner
Period of report
Jul 27, 2026
Accepted (ET)
Jul 29, 2026 · 4:21 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001853921
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 27, 2026 | C | 12,511 | — | A | 603,547 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A-1 Preferred StockF1 | — | Jul 27, 2026 | C | 74,088 | D | — | — | Common Stock | 12,511 | 0 | D |
Explanation of responses
- F1Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.